EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Focal Adhesion Kinase Signaling Promotes Metastasis of BRAFV600E-Driven Melanoma

Karly A. Stanley, MiKaela N. Field, Adriene M. Pavek, A. Paulina Medellin, Savannah N. Pettey, Mercedes C. Randhahn, Evan M. VanBrocklin, Caroline A. Connolly, Garrett L. Otrimski, Gennie L. Parkman, David A. Kircher, Benjamin Izar und 5 weitere

Cancers · 14.11.2026 · 18 (22) · 3646

DOI: 10.3390/cancers18223646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.11.2026. Verfasst von Karly A. Stanley und 16 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Huntsman Cancer Foundation, National Institutes of Health, University of Utah.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Despite several FDA-approved therapies, metastatic melanoma remains a major clinical challenge, particularly in patients with brain metastases, which are associated with treatment failure and melanoma-related mortality. The molecular mechanisms underlying the development of melanoma brain metastasis remain incompletely understood.

Methods

Building on our prior discovery that AKT1 activates focal adhesion kinase (FAK), we analyzed clinical-genomic data to evaluate the association between PTK2 mRNA expression and overall survival in melanoma cohorts. For functional assessment, we used complementary in vitro and in vivo approaches to investigate the effects of FAK overexpression, FAK activation, FAK kinase-dependence, and expression of FAK-related non-kinase (FRNK) on cell proliferation, migration, and invasion. Complementary syngeneic and genetically engineered mouse models were used to assess tumor growth and metastatic dissemination.

Results

High PTK2 (FAK) mRNA expression was associated with shorter overall survival in melanoma cohorts, including patients with BRAF-mutant melanoma treated with BRAF and MEK inhibitors. Pharmacologic MEK inhibition increased FAK phosphorylation at the activating Y397 site, suggesting a potential compensatory response to MAPK pathway inhibition. Functional studies implicated FAK expression and signaling in melanoma cell migration, invasion, tumor growth, and metastatic dissemination. Expression of a kinase dead FAK mutant markedly impaired tumor growth and metastasis in vivo.

Conclusions

These findings implicate FAK signaling in melanoma progression and metastatic dissemination. The observed effects of FAK mutants support the further investigation of FAK kinase activity as a therapeutic target. In addition, increased FAK Y397 phosphorylation following MEK inhibition provides a rationale for evaluating combined FAK and MAPK pathway inhibition clinically in patients with advanced melanoma.

Förderung

  • Huntsman Cancer Foundation
  • National Institutes of Health
  • University of Utah

Zitieren

APA

Stanley, K. A., Field, M. N., Pavek, A. M., Medellin, A. P., Pettey, S. N., Randhahn, M. C., VanBrocklin, E. M., Connolly, C. A., Otrimski, G. L., Parkman, G. L., Kircher, D. A., Izar, B., Young, A., Neuendorf, H. M., McMahon, M., VanBrocklin, M. W., & Holmen, S. L. (2026). Focal Adhesion Kinase Signaling Promotes Metastasis of BRAFV600E-Driven Melanoma. Cancers, 18(22), 3646. https://doi.org/10.3390/cancers18223646

Vancouver

Stanley KA, Field MN, Pavek AM, Medellin AP, Pettey SN, Randhahn MC, et al. Focal Adhesion Kinase Signaling Promotes Metastasis of BRAFV600E-Driven Melanoma. Cancers. 2026;18(22):3646. doi:10.3390/cancers18223646

BibTeX
@article{Stanley2026,
  author = {Stanley, Karly A. and Field, MiKaela N. and Pavek, Adriene M. and Medellin, A. Paulina and Pettey, Savannah N. and Randhahn, Mercedes C. and VanBrocklin, Evan M. and Connolly, Caroline A. and Otrimski, Garrett L. and Parkman, Gennie L. and Kircher, David A. and Izar, Benjamin and Young, Alexandra and Neuendorf, Hannah M. and McMahon, Martin and VanBrocklin, Matthew W. and Holmen, Sheri L.},
  title = {Focal Adhesion Kinase Signaling Promotes Metastasis of BRAFV600E-Driven Melanoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3646},
  doi = {10.3390/cancers18223646}
}
Kostenlos starten →